Generated with Avocode.Line 2Line 3

AI Insights to Impact:
Virtual Panel Discussion with Drs Kumar, Heit and Ms Philpot

Tuesday, December 10, 4:30 PM PST

Rapid for Trials

Quickly Identify + Enroll Clinical Trial Candidates

Rapid for Trials streamlines clinical trial screening and enrollment workflow. A feature within the Rapid mobile app, Rapid for Trials delivers results from Rapid clinical modules to study team members’ mobile devices, streamlining communications, maximizing screening potential and reducing time to enrollment.

The Rapid platform has been used to select patients and conduct core lab analysis for some of the most influential stroke clinical trials ever performed – all 6 randomized trials had positive results and published in the NEJM. RapidAI for Trials offers unparalleled clinical trial expertise.

CHARM-Notification-Aspects@3x (4)
CHARM-Notification-Patient-Card@3x (2)
CHARM-Patient-Images@3x (2)
CHARM-Notification-Patient-Status (2)-1
GREATER VOLUME. STREAMLINED ENROLLMENT.
TRANSPARENT ANALYTICS.

Rapid for Trials provides:

notifications

Custom Mobile Notifications

Alerts are sent immediately to the research team when potential study candidates are identified – with customizable alert configurations.

real-time-site

Real-Time Site-Level Analytics

Analytics deliver transparency of potential patient volumes at participating sites.

compliant-communication

Rapid Workflow and HIPAA-Compliant Communication

Study team members are provided access to source imaging data as well as clinical data.

expertise and-assistance

RapidAI Team Expertise and Assistance

Study team members are provided access to source imaging data, as well as clinical data.

Multiple Therapies Covered

Rapid for Trials can be used across multiple therapies, including stroke, aneurysm and pulmonary embolism (PE).

Clinical Trial Workflow

Patient Identification
Notification-Triggered-2 (2)
Notification Triggered
View Screen
Notification Triggered
Notification-Triggered-2 (2)
Immediate Access to Results
Patient-Flagged-in-the-App (2)
Patient Flagged in the App
View Screen
Patient Flagged in the App
Patient-Flagged-in-the-App (2)
Results-&-Criteria-Viewable (1)
Results & Criteria Viewable
View Screen
Results & Criteria Viewable
Results-&-Criteria-Viewable (1)
Research Team Communications
Team-Collaboration-for-Enrollment (1)
Team Collaboration for Enrollment
View Screen
Team Collaboration for Enrollment
Team-Collaboration-for-Enrollment (1)
KEY BENEFITS

DRIVE RELEVANT PATIENT VOLUME

Rapid for Trials helps identify relevant patients–enhancing the volume and quality of trial registrants.

SHARPEN YOUR FUNNEL

Rapid offers a suite of modules to identify patients that meet study inclusion and exclusion criteria.

STREAMLINE ENROLLMENT

Automated quantification of eligibility criteria is available immediately to improve coordinator speed and efficiency while screening patients for enrollment.

ANALYZE WITH EASE

Get site-level visibility into scan volume based on site specific inclusion and exclusion criteria.

Icon_star

Only the best for your patients

The Rapid platform has been used in the most influential stroke clinical trials in the world for both patient selection and core lab analysis.

DEFUSE 2, Lancent Neurology
CRISP, Annals of Neurology
EXTEND IA, NEJM
SWIFT PRIME, NEJM
DAWN, NEJM
DEFUSE 3, NEJM
RESILIENT, NEJM
AURORA, Lancet and JAMA Neurology
TIMELESS (Genentech) - ongoing
CHARM (Biogen) - ongoing
SELECT 2 - just finished
APRIL - ongoing
LUMOSA - ongoing
REPERFUSE - ongoing
EVACUATE - ongoing
ENCHANTED2 - ongoing
ANGEL-ASPECT - ongoing
Australian Pediatric Stroke Trial - ongoing
PRECISE - ongoing
RESILIENT EXTEND - ongoing
real-time-site-level-analytics

RapidAI Insight - Real-Time Site-Level Analytics

The RapidAI Insights product provides a clinical trial study dashboard to aid in tracking site-level performance, such as number of scans per site and number of potential patients identified based on each of the modules. Dashboards can be customized to the unique requirement of trial sponsors.

“ We used RAPID in the EXTEND, EXTEND-IA and EXTEND-IA TNK randomized trials at over 20 sites across Australia and New Zealand. It’s straightforward to install and works with the full range of CT and MR devices and PACS systems. The fully automated results are robust to common artefacts, easily interpretable and provide standardization across sites with a range of imaging experience.”

Bruce Campbell, MBBS(Hons), BMedSc, PhD, FRACP​
University of Melbourne and Melbourne Health (Royal Melbourne Hospital)​

Discover how Rapid for Trials can accelerate your clinical trial enrollment today.

Talk to an Expert